Joseph Mikhael M.D.

Dr. Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Chief Medical Officer of the International Myeloma Foundation (IMF).

Dr. Mikhael is a consultant hematologist and Director of Myeloma Research at the HonorHealth Research Institute where he conducts phase 1 clinical trials. He just a completed a term as Councilor on the American Society of Hematology Executive. He also recently led the ASCO guidelines for multiple myeloma.

Dr. Mikhael was recently a hematologist at Mayo Clinic Arizona where he served as a Professor at the Mayo College of Medicine, Associate Dean of Graduate Medical Education and Deputy Director - Education of the Mayo Clinic Cancer Center. He has been recognized with numerous awards in education including being in the Mayo Clinic Resident and Fellow Association Hall of Fame as Educator of the Year. He was also recently named in the Top 100 Doctors in the United States.

Dr. Mikhael did his initial medical school training in Ottawa, Canada, followed by his Hematology Residency at Princess Margaret Hospital in Toronto. He then did a Multiple Myeloma Fellowship there along with a Masters’ Degree in Education from the University of Toronto. He was on staff at PMH until being recruited to Mayo Clinic in 2008

He specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis and Waldenstrom’s macroglobulinemia. Dr. Mikhael is currently the principal investigator of many clinical trials, primarily in multiple myeloma. His other clinical research interests also include pharmaco-economics, communication skills and media relations. He has published over 150 peer reviewed articles in these fields. He lectures internationally on a regular basis. He is an active member of the International Myeloma Working Group and serves on the editorial board of the Journal of Clinical Oncology.

Dr. Mikhael is leading the IMF African American initiative, known as M-Power, which seeks to improve the care delivered to African Americans with myeloma – a disease with double the incidence in African Americans than Caucasians. Dr. Mikhael also spends about 20% of his time in the third world seeking ways to enhance access to myeloma therapies in underprivileged countries.

Publications

Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012 May 10; 119: (19)4391-4. PMID:22331188 PMCID:3557400 DOI:10.1182/blood-2011-11-390930

Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr; 88: (4)360-76. PMID:23541011 DOI:10.1016/j.mayocp.2013.01.019

Mikhael JR, Reeder CB, Libby EN, Costa LJ, Bergsagel PL, Buadi F, Mayo A, Nagi Reddy SK, Gano K, Dueck AC, Stewart AK. Phase IbII trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol. 2015 Apr; 169: (2)219-27. PMID:25683772 PMCID:4521972 DOI:10.1111/bjh.13296

Sung L, Rego E, Riva E, Elwood J, Basso J, Clayton CP, Mikhael J. Development and Evaluation of a Hematology-Oriented Clinical Research Training Program in Latin America. J Cancer Educ. 2016 Mar 15; PMID:26976436 DOI:10.1007/s13187-016-1015-4

Mikhael J. Management of Carfilzomib-Associated Cardiac Adverse Events. Clin Lymphoma Myeloma Leuk. 2016 May; 16: (5)241-5. PMID:26907720 DOI:10.1016/j.clml.2016.01.008

Lipe B, Vukas R, Mikhael J. The role of maintenance therapy in multiple myeloma. Blood Cancer J. 2016 Oct 21; 6: (10)e485. PMID:27768093 PMCID:5098261 DOI:10.1038/bcj.2016.89

Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 07; 130 (10):1198-1204 Epub 2017 July 06 PMID:28684537 PMCID:5606008 DOI:10.1182/blood-2017-05-782961

Mikhael JR. Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival-In Most. J Clin Oncol. 2017 Oct 10; 35 (29):3269-3271 Epub 2017 Aug 23 PMID:28834440 doi:10.1200/JCO.2017.74.7014

Costello C, Mikhael JR. Therapy sequencing strategies in multiple myeloma: who, what and why? Future Oncol 2018 Jan; 14 (2):95-99 Epub 2017 Dec 08

Marshall AL, Jenkins S, Mikhael J, Gitlin SD. Determinants of hematology-oncology trainees' postfellowship career pathways with a focus on nonmalignant hematology. Blood Adv. 2018 Feb 27; 2 (4):361-369

Laubach JP, van de Donk N, Davies FE, Mikhael J. Practical Considerations for Antibodies in Myeloma. 2018

ASCO Educational Book pp. 667–674.

Podcasts Featuring Joseph Mikhael

Episode 31: Make It Personal - Recent events and social protests h... Oct 20, 2020